Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial hypercholesterolemia (FH). The mechanism by which mutations in the LDLR affecting the transmembrane domain of the receptor cause FH has not been thoroughly investigated. In this study, we have selected 12 naturally occurring mutations affecting the transmembrane domain and studied their effect on the LDLR. The main strategy has been to transiently transfect HepG2 cells with mutant LDLR plasmids and to study the mutant LDLRs in cell lysates and in media by western blot analysis. The most striking finding was that mutation p.L799R led to secretion of the entire 160 kDa mature L799R-LDLR. Residue 799 Leu is in the middle of the 22-residue transmembrane domain, and introduction of a basic residue in the hydrophobic core of the transmembrane domain could prevent L799R-LDLR from being correctly recognized and integrated in the membrane by the Sec61 translocon complex. This would then lead to translocation of the entire L799R-LDLR into the lumen of the endoplasmic reticulum. Mutation p.L799R should be considered a member of a separate class of FH-causing mutations that affects the insertion of the LDLR in the cell membrane.
Introduction
The low-density lipoprotein receptor (LDLR) plays a key role in lipid metabolism by clearing cholesterol-rich low-density lipoprotein (LDL) from plasma (1) . Mutations in the LDLR gene (OMIM #606945), which leads to defective LDLRs, cause familial hypercholesterolemia (FH), which is characterized by autosomal dominant hypercholesterolemia, xanthomas and premature coronary heart disease (1) .
The LDLR is a Type 1 transmembrane protein consisting of 860 residues including a 21-residue signal peptide (2) . During transport through the Golgi apparatus, the LDLR undergoes post-translational modifications whereby O-linked sugars are added and N-linked sugars are modified. As a consequence of these modifications, the apparent molecular weight increases from 120 to 160 kDa (3) . At the cell surface, the LDLR is inserted in the cell membrane and is further concentrated in clathrin-coated pits for receptor-mediated endocytosis of LDL (4) .
The ectodomain of the LDLR consists of three functional domains (5) . These are the N-terminal ligand-binding domain, a domain with a high degree of homology with the precursor for the epidermal growth factor and a domain enriched in O-linked sugars. The transmembrane domain consists of 22 amino acids, and the cytoplasmic domain consists of 50 amino acids and contains the motifs required for concentrating the LDLRs in clathrin-coated pits (5) .
More than 1700 different mutations in the LDLR have been found to cause FH (www.ucl.ac.uk/ldlr), and these may be classified into five classes based on their effects on the LDLR (6) . Class 1 mutations prevent the synthesis of any immunodetectable LDLR, and Class 2 mutations make the LDLR completely (Class 2a) or partially (Class 2b) retained in the endoplasmic reticulum (ER). Class 3 mutations make the LDLR defective in binding LDL at the cell surface. Class 4 mutations disrupt the LDLR's ability to concentrate in clathrin-coated pits, and Class 5 mutations result in a mutant LDLR, which, after having internalized LDL, is degraded intracellulary.
The mechanism by which mutations in the different domains cause defective LDLRs has been well characterized except for mutations that affect the transmembrane domain depicted in Figure 1 . However, we have recently reported that mutation p.G805R (c.2413G>A, ref. seq.: NM_000527.3) in exon 17 of the LDLR, which affects the transmembrane domain, causes a reduced number of cell membrane-bound LDLRs due to ectodomain cleavage by a metalloproteinase in the ER (7) . As a consequence, the ectodomain of the mutant LDLR is largely confined to the lumen of the ER for subsequent secretion into the extracellular space. To further study the mechanism by which mutations affecting the transmembrane domain cause FH, we have selected a series of naturally occurring mutations and investigated their effect on the LDLR.
Results

Western blot analyses of mutant LDLRs
HepG2 cells were transiently transfected with wild-type (WT) or mutant LDLR plasmids, and the cells were cultured in the presence or absence of the γ-secretase inhibitor N-(N-(3,5-difluorophenacetyl)--alanyl)-S-phenylglycine t-butyl ester (DAPT) in order to study whether the mutations affected γ-secretase cleavage of the transmembrane domain. Such γ-secretase cleavage is the consequence of ectodomain cleavage of the LDLR at the cell surface or in endosomes (7, 8) . Western blot analyses of the LDLRs in lysates or in culture media were performed using an antibody against the C-terminal HA tag or an antibody against the ligand-binding domain of the LDLR, respectively (Fig. 2) . Mutation p.G805R was included as a control for a mutation that prevents γ-secretase cleavage (7).
In the medium of cells transfected with the WT-LDLR plasmid, a 140 kDa ectodomain fragment was observed. In the lysate of cells transfected with the WT-LDLR plasmid, the 160 kDa mature form and the 120 kDa precursor form were observed in addition to a 140 kDa degradation product (Δ1-4-LDLR), where ligand-binding repeats 1-4 have been cleaved off (9) , and a 17 kDa C-terminal fragment caused by ectodomain cleavage close to the cell membrane ( Fig. 2) (8) . The amount of the latter fragment was markedly increased when the cells had been cultured in the presence of DAPT to prevent γ-secretase cleavage ( Fig. 2) (8) .
The amounts of the different mutant LDLRs in cell lysates varied as determined by western blot analysis (Fig. 2) . This could be due to different transfection efficiencies or differences in the efficiency of membrane insertion. Mutations p.I792F, p.P795H, p.V797L, p.799del and p.V800D did not appear to have any major effect on the respective mutant LDLRs (Fig. 2) . Mutations p.803_808dup, p.L804P and p.V806D appeared to be somewhat defective in γ-secretase cleavage as the ability of DAPT to increase the amounts of the respective 17 kDa C-terminal fragments was markedly lower than for the WT-LDLR. However, these three mutants were more sensitive to γ-secretase cleavage than the previously reported mutant p.G805R-LDLR (Fig. 2) (7) . Mutations p.798_800del and p.799_801del had higher amounts of shed 140 kDa ectodomain, which suggest increased susceptibility to cleavage by a metalloproteinase. Mutation p.803_808del appeared to have a reduced amount of the 160 kDa form relative to that of the 120 kDa form. This could be due to rapid degradation of the 160 kDa mature form at the cell membrane.
The western blot of L799R-LDLR was markedly different from that of the other LDLR mutants (Fig. 2) . In the medium of cells transfected with the L799R-LDLR plasmid, an additional 160 kDa fragment and a fainter ∼300 kDa fragment were observed (Fig. 2) . Only a faint band representing the 160 kDa mature form of L799R-LDLR was observed in the lysate. Moreover, virtually no membrane-bound 140 kDa Δ1-4-LDLR degradation product and no membrane-bound 17 kDa C-terminal fragment were observed. These findings indicate that there are no or markedly reduced amounts of cell-membrane-bound L799R-LDLR in transfected cells. Because incubation of the cells in the presence of the proteasomal inhibitor epoxomicin did not increase the amount of the 120 kDa precursor form, the reduced amount of the 120 kDa precursor form was not due to proteasomal degradation (Supplementary Material, Fig. S1 ). Neither the lysosomal/proteasomal inhibitor MG132, the lysosomal inhibitor leupeptin nor ammonium chloride, which prevents acidification of endosomal compartments, increased the amount of the 120 kDa precursor form (data not shown). Thus, it is unlikely that the low level of the 120 kDa precursor form of L799R-LDLR was due to proteasomal or lysosomal degradation.
The 160 kDa L799R-LDLR fragment in the medium is not caused by ectodomain shedding by a metalloproteinase It has previously been shown that shedding of the 140 kDa ectodomain LDLR from HepG2 cells transfected with the WT-LDLR plasmid is caused by a metalloproteinase, as shedding could be prevented by the metalloproteinase inhibitor batimastat (7, 10) . To study whether a metalloproteinase was involved in the generation of the 160 kDa L799R-LDLR fragment in the medium, HepG2 cells transfected with the L799R-LDLR plasmid were cultured in the presence of batimastat (Fig. 3) . Whereas the 140 kDa L799R-LDLR fragment in the medium could not be detected in the presence of batimastat, similarly to that of the 140 kDa WT-LDLR fragment, the amount of the 160 kDa L799R-LDLR fragment in the medium was not affected (Fig. 3) . Thus, the 160 kDa L799R-LDLR fragment in the medium was not caused by the action of a metalloproteinase.
The entire 160 kDa L799R-LDLR is secreted into the culture medium
If the 160 kDa L799R-LDLR fragment in the medium represented secretion of the entire L799R-LDLR, it should also be detectable by western blot analysis using an antibody against the C-terminal HA tag. Thus, medium of cells transfected with the L799R-LDLR plasmid was subjected to immunoprecipitation (IP) before analysis by western blot analysis. As can be seen from Figure 4 , the immunoprecipitated 160 kDa L799R-LDLR could be detected by the anti-HA antibody. Thus, the entire 160 kDa L799R-LDLR is secreted into the culture medium. The notion that L799R-LDLR fails to be incorporated in the cell membrane was supported by confocal laser-scanning microscopy using an antibody against Human Molecular Genetics, 2015, Vol. 24, No. 20 | 5837 the LDLR (data not shown). It is assumed that the ∼300 kDa L799R-LDLR fragment observed in the medium (Fig. 2 ) reflects a dimeric form of L799R-LDLR, which then has an actual molecular weight of 320 kDa. When a 27 kDa enhanced yellow fluorescent protein (EYFP) was fused to the C-terminus of L799R-LDLR, L799R-LDLR was rescued from being secreted (Supplementary Material, Fig. S2 ). This finding suggests that a string of hydrophobic residues within EYFP is able to anchor the fusion protein in the ER membrane.
Role of Leu 799
To study whether secretion of the 160 kDa L799R-LDLR was due to the lack of Leu 799 or to the presence of Arg 799 , the effect of mutation p.L799A was studied. As determined by western blot analysis of lysates from HepG2 cells transiently transfected with the L799A-LDLR plasmid, no 160 kDa L799A-LDLR fragment was observed in the medium (Fig. 5) . Moreover, L799A-LDLR was subjected γ-secretase cleavage similarly to that of the WT-LDLR (Fig. 5) . Thus, it is the presence of Arg 799 and not the absence of Leu 799 that causes secretion of L799R-LDLR. This notion is also supported by the finding that deletion of Leu 799 caused by mutation p.799del did not appear to have any impact on the LDLR (Fig. 2) .
Role of arginines in the transmembrane domain
Residue 799 is in the middle of the transmembrane domain with 10 residues in the outer part and 11 residues in the inner part of the membrane (Fig. 1 ). To further study the effect of having a positively charged amino acid within the hydrophobic core of the cell membrane, three of the surrounding residues were mutated to arginines. HepG2 cells were transiently transfected with the respective mutant LDLR plasmids and the media and lysates were subjected to western blot analysis (Fig. 6 ). V797R-LDLR behaved similarly to L799R-LDLR. The 160 kDa form of L798R-LDLR was also observed in the medium, but also the 17 kDa C-terminal fragment could be detected. This may reflect that a certain proportion of L798R-LDLR was membrane-bound and was subjected to ectodomain cleavage to generate a membrane-bound 17 kDa C-terminal fragment. However, the amount of the 17 kDa C-terminal L798R-LDLR fragment was not markedly increased in the presence of DAPT. This indicates that L798R-LDLR is defective in cleavage by γ-secretase. For V800R-LDLR, virtually no mature 160 kDa form was observed in lysates and very little was observed in the culture medium. Rather, there was a markedly increased amount of the 120 kDa precursor V800R-LDLR relative to that of the 160 kDa mature V800R-LDLR in lysate. This could indicate that the 160 kDa mature V800R-LDLR is very unstable. Markedly reduced amounts of the 160 kDa V800R-LDLR in the cell membrane is also supported by the markedly reduced amounts of the membrane-bound C-terminal V800R-LDLR fragment in cell lysates, which also was shorter than the usual size of 17 kDa (Fig. 2) . Thus, mutation p.V800R makes the mutant LDLR undergo ectodomain cleavage closer to the C-terminus. This could possibly reflect altered conformation of the transmembrane domain as 800 Arg may try to escape from the hydrophobic core of the membrane. 
Evolutionary conservation of 799 Leu
The human LDLR sequence and homologous sequences from 3 other primates, 15 additional mammals, 2 reptiles, a frog and 5 species of fish, in total 30 sequences, were obtained from the Ensembl (11) and UniProt (12) databases. The sequences were aligned, and a segment corresponding to the C-terminus of the LDLR plasmid or mutant LDLR plasmids containing the indicated mutations. The cells were cultured in the presence or absence of the γ-secretase inhibitor DAPT (10 µM), and the lysates and culture media were subjected to western blot analysis. An antibody against the C-terminal HA tag was used to probe the LDLRs in lysates, and an antibody against the LDLR ligand-binding domain was used to probe the LDLRs in the media. No LDLR was found in the media of cells transfected with empty plasmid (data not shown). In the media, molecular weight markers are shown, and in the lysates, the 160 kDa mature LDLR, a 140 kDa degradation product (Δ1-4-LDLR, lacking ligand-binding repeats 1-4) (9), the 120 kDa precursor LDLR and a 17 kDa C-terminal cleavage fragment are indicated. The amount of β-tubulin in the lysates was used as a loading control. One representative of three separate experiments is shown. ectodomain, the transmembrane domain and the N-terminus of the cytoplasmic tail is shown in Figure 1 .
The alignment shows a complete lack of residues with charged side chains in the transmembrane domain and clearly demonstrates a strong evolutionary selection against mutations that introduce charged residues in the hydrophobic lipid bilayer. Residue 799 Leu is not evolutionary conserved as such, but all mutations within the vertebrate lineage at this position have resulted solely from substitution of one strongly hydrophobic residue for another (Fig. 1) .
Discussion
In this study, we have performed a series of experiments to study the mechanism by which 12 mutations affecting the transmembrane domain of the LDLR cause FH.
The main strategy has been to perform western blot analyses of lysates and media from HepG2 cells transiently transfected with plasmids containing the various LDLR mutations. This strategy should be able to detect Class 1 and 2 mutations as well as mutations that affect membrane insertion of the mutant LDLRs. It is unlikely that mutations in the transmembrane domain of the LDLR could affect the binding of LDL to the LDLR at the cell surface or the interaction between adaptor proteins and the cytoplasmic domain of the LDLR, and thereby represent Class 3 or 4 mutations, respectively. It is also unlikely that mutations in the transmembrane domain could interfere with the release of LDL from the LDLR in the sorting endosome and thereby represent Class 5 mutations. Thus, the strategy used should be able to determine the mechanism by which mutations affecting the transmembrane domain of the LDLR cause FH.
Mutation p.L799R had the most distinct western blot pattern with additional 160 and 320 kDa fragments observed in the culture medium of transfected cells. Using an antibody against the C-terminus of L799R-LDLR, it was shown that the 160 kDa fragment in the medium represented the mature L799R-LDLR. Thus, mutation p.L799R, affecting a residue in the middle of the transmembrane domain, prevents L799R-LDLR from being inserted into the ER membrane leading to its secretion. Studies of another Type 1 transmembrane protein, where the transmembrane domain has been replaced with that of L799R-LDLR, could provide further support for this notion. It is assumed that the 320 kDa L799R-LDLR fragment represents a dimer of the 160 kDa form. The underlying mechanism for dimerization could be to prevent aqueous exposure of hydrophobic residues within the transmembrane domain. Mutation p.L799R in exon 17 in the LDLR has been identified in a subject of white ethnicity living in the Czech Republic (13) and is predicted to be pathogenic by the software programs PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) and SIFT (http:// sift.jcvi.org) ( Table 1 ). However, it was predicted to be a neutral variant by the software program Mutation Taster (http://www. mutationtaster.org/) ( Table 1) .
Most vertebrate membrane proteins with a signal peptide are inserted into the ER membrane as nascent polypeptides from the Sec61 translocon protein-conducting channel (22) . While nonhydrophobic segments of the newly synthesized protein pass through the translocon channel, the hydrophobic segments, i.e. the transmembrane helices, are not translocated across the membrane, but are instead inserted sideways into the lipid bilayer. Von Heijne et al. have shown that transmembrane helices normally inserted in the membrane by the translocon are translocated into the ER lumen upon mutation of single residues in the transmembrane segment (23) . Especially, damaging for membrane integration are mutations that introduce charged residues in the membrane, particularly if they are incorporated close to the middle of the transmembrane segment.
Apparently, when the WT single-pass membrane protein LDLR is synthesized, the signal peptide is recognized by the translocon complex, the ectodomain is translocated into the ER lumen, the transmembrane domain is shuttled into the ER membrane by the translocon, while the cytoplasmic tail remains in the cytoplasm. In the case of L799R-LDLR, the translocon is not recognizing the transmembrane domain, and the full-length protein is translocated into the lumen. Figure 1 clearly shows that charged residues in the transmembrane domain are evolutionary not beneficial and are likely to disrupt receptor function by inefficient membrane insertion. It should be noted that not all mutations introducing charged residues in the membrane generated in the present study are deleterious for membrane insertion. While V797R-LDLR, and to some degree, L798R-LDLR, gave rise to fully translocated and secreted protein, V800R-LDLR (Fig. 6) did not appear to translocate fully across the membrane. However, mutation p.V800R was clearly pathogenic as only a very small amount of the 160 kDa mature V800R-LDLR was observed in lysates of transfected cells. The different outcomes of introducing charged residues in the mid-section of the transmembrane domain might reflect the complexity of the interaction between the translocon channel and the nascent peptide.
The secreted full-length L799R-LDLR could affect the plasma LDL cholesterol levels in opposite ways in FH heterozygotes. Firstly, secreted L799R-LDLR could bind LDL in plasma and prevent LDL from being cleared by the LDLR synthesized from the normal allele. This would lead to increased levels of LDL cholesterol. Secondly, secreted L799R-LDLR could bind proprotein convertase subtilisin/kexin type 9 (PCSK9) in plasma and prevent PCSK9 from degrading the cell-surface LDLR synthesized from the normal allele. This would lead to decreased levels of LDL cholesterol. However, to our knowledge, no lipid profiles of heterozygous p.L799R subjects have been reported, and possible effects of the secreted L799R-LDLR on LDL cholesterol levels will therefore remain speculative.
To our knowledge, this is the first time a naturally occurring mutation in the transmembrane domain of a Type 1 transmembrane protein has been shown to prevent the mutant protein from being inserted in the cell membrane and lead to its secretion. However, there are several examples of both single-and multipass membrane proteins where mutations that introduce charged residues within the transmembrane domain lead to genetic diseases (24) (25) (26) . By introducing hydrophilic residues within the hydrophobic lipid bilayer, γ-secretase cleavage and intracellular signaling could be affected, the mutant protein could undergo proteasomal degradation or the mutant protein could be cleaved by a metalloproteinase leading to ectodomain shedding.
Of the 12 naturally occurring mutations that were studied, mutations p.I792F, p.P795H, p.V797L, p.L799del and p.V800D were most likely normal genetic variants that do not cause FH. Mutation p.I792F has previously been characterized as being a Class 2a mutation (6). However, our data are at variance with this classification because the relative amount of the 120 kDa precursor form to that of the 160 kDa mature form of I792F-LDLR, was similar to that of the WT-LDLR. Mutations p.P795H (14) , p.L799del (18) and p. V800D (19) have been identified in subjects with a clinical diagnosis of FH. However, no functional studies have been reported regarding their pathogenicity. Our data indicate that these mutations most likely are normal genetic variants, although mutation p.P795H is predicted to be pathogenic by the use of three bioinformatics tools (Table 1) . Mutation p.V800D is predicted to be a normal genetic variant by the use the same set of bioinformatics tools (Table 1) . Mutation p.V797L (15) , which involves the last nucleotide of exon 16, could possibly weaken the donor splice site in intron 16. Such a weakening is suggested by the bioinformatics programs SpliceSiteFinder-like (http://www.genet.sickkids.on.ca), MaxEntScan (http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq. html) and GeneSplicer (http://ccb.jhu.edu/software/genesplicer/), but not by the programs NNSPLICE (http://www.fruitfly.org/ Table 1) .
Mutations p.803_808dup (15) , p.L804P (20) and p.V806D (21) have been identified in patients with a clinical diagnosis of FH. However, no functional studies have been reported. Our data have shown that these three mutations cause defective γ-secretase cleavage, but otherwise the respective mutants appear to be similar to the WT-LDLR. Whether γ-secretase cleavage of the transmembrane domain has any significant biological function is unknown. Moreover, mutations p.L804P and p.V806D were predicted to be normal genetic variants by the use of bioinformatics tools (Table 1) . Mutations p.798_800del (16) and p.799_801del (17) had increased amounts of shed 140 kDa ectodomain, which suggest increased susceptibility to cleavage by a metalloproteinase in the ER or at the cell surface. Mutation p.803_808del (TP Leren, unpublished data) caused a reduced amount of the 120 kDa precursor form, and an even more reduced amount of the 160 kDa mature form. This could indicate that this mutant is defective in insertion in the ER membrane and is also rapidly degraded at the cell surface. In conclusion, characterization of the mechanism by which mutations affecting the transmembrane domain of the LDLR cause FH has identified a sixth class of mutations in the LDLR as a cause of FH. This class consists of mutations that interfere with the normal insertion of the LDLR in the cell membrane. As a consequence, the mutant LDLR may be secreted, may undergo metalloproteinase cleavage leading to ectodomain shedding or may undergo rapid degradation at the cell surface.
Materials and Methods
Mutations
The mutations studied (Table 1) were selected from the database www.ucl.ac.uk/ldlr, except for mutation p.803_808del, which has been identified in our own laboratory (TP Leren, unpublished data). Mutation numbering was based on the cDNA sequence with nucleotide +1 being the A of the ATG translation initiation codon. The translation initiation codon is codon 1.
Reagents
DAPT and epoxomicin were from Sigma-Aldrich Corp. (St Louis, MO). Batimastat was from Calbiochem (Darmstadt, Germany). All other reagents were standard laboratory reagents.
Cell cultures
HepG2 cells (European Collection of Cell Cultures, Wiltshire, UK) were cultured in modified Eagle's medium (Gibco Life Technologies, Paisley, UK) containing 10% fetal bovine serum, 2 mM -glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin and non-essential amino acids. The cells were grown on collagencoated plates from BD Biosciences (San Jose, CA).
Plasmids and transfections
To generate a WT-LDLR plasmid containing a C-terminal HA tag, the plasmid pcDNA4-LDLR-EYFP (27) was used as a template for polymerase chain reaction to amplify LDLR cDNA containing a HA tag, by using the primers LDLR-HA fwd and LDLR-HA rev (Supplementary Material, Table S1 ). These primers contain the restriction sites for Bsu36I and KpnI, respectively. The latter primer also contains a stop codon. The amplified fragment was TAcloned (Invitrogen, Carlsbad, CA) and digested with the restriction enzymes Bsu36I and KpnI before ligation into a similarly digested pcDNA4-LDLR-EYFP to generate the plasmid pcDNA4-LDLR-HA. This plasmid was used as a template to generate mutations that affect the transmembrane domain using QuickChange II XL Mutagenesis Kit (Agilent Technologies, Santa Clara, CA) according to the manufacturer's instructions. The oligonucleotide sequences used for mutageneses are listed in the Supplementary Material, Table S1 . The integrity of the plasmids was confirmed by DNA sequencing. Transient transfection of HepG2 cells with HA-tagged LDLR plasmids was performed using FuGENE HD (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer's instructions. Twenty-four hours after transfection, the cells were washed in phosphate-buffered saline (GE Healthcare Life Sciences, South Logan, UT), and the medium was changed to Opti-MEM reduced serum medium without phenol red (Gibco Life Technologies, Paisley, UK). The cells were grown for another 24 h before lysates were prepared, and culture media were harvested.
Immunoprecipitation and western blot analyses
IP was carried out using Protein G Mag Sepharose (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to the manufacturer's instructions. Briefly, a rabbit polyclonal anti-HA antibody (Invitrogen, Carlsbad, CA) was bound to magnetic beads for 1 h at 4°C. Culture media from transfected HepG2 cells were harvested and centrifuged for 5 min at 5000 rpm to remove cell debris. The antibody-bound magnetic beads were then added to the supernatant (500 μl) for an over-night incubation at 4°C. Western blot analyses of cell lysates (30 µg) or culture media (20 µl) were carried out as previously described (7, 28 ). An anti-HA antibody (Invitrogen, Carlsbad, CA) or a rabbit polyclonal anti-LDLR antibody (Fitzgerald Industries International, Concord, MA) raised against the linker region between ligand-binding repeats 4 and 5 were used to detect the LDLR. β-Tubulin was used as a loading control and was detected by a rabbit anti-β-tubulin antibody (USBiological, Salem, MA).
